The Diabetes Syndrome – A Collection of Conditions with Common, Interrelated Pathophysiologic Mechanisms

References

• Schwartz SS, Epstein S, Corkey BE, et al. The time is right for a new classification system for diabetes: rationale and implications of the β-cell-centric classification schema. Diabetes Care. 2016;39(2):179–186. doi:10.2337/dc15-1585
   PubMed Web of Science ®Google Scholar
• Schwartz SS, Epstein S, Corkey BE, et al. A unified pathophysiological construct of diabetes and its complications. Trends Endocrinol Metab. 2017;28(9):645–655. doi:10.1016/j.tem.2017.05.005
   PubMed Web of Science ®Google Scholar
• Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–1625. doi:10.2337/diabetes.54.6.1615
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Cardiometabolic risk, type 2 diabetes and cardiovascular disease; 2015. Available from: https://professional.diabetes.org/sites/professional.diabetes.org/files/media/cardiometabolicrisk2015.pdf. Accessed March 10, 2021.
   Google Scholar
• Aksentijevich M, Lateef SS, Anzenberg P, et al. Chronic inflammation, cardiometabolic diseases and effects of treatment: psoriasis as a human model. Trends Cardiovasc Med. 2019;30(8):S1050-1738(19)30151-3. doi:10.1016/j.tcm.2019.11.001
   PubMed Web of Science ®Google Scholar
• Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–1048. doi:10.1016/j.metabol.2015.12.012
   PubMed Web of Science ®Google Scholar
• Holm JG, Thomsen SF. Type 2 diabetes and psoriasis: links and risks. Psoriasis (Auckl). 2019;9:1–6. doi:10.2147/PTT.S159163
   PubMed Web of Science ®Google Scholar
• Mamizadeh M, Tardeh Z, Azami M. The association between psoriasis and diabetes mellitus: a systematic review and meta-analysis. Diabetes Metab Syndr. 2019;13(2):1405–1412. doi:10.1016/j.dsx.2019.01.009
   PubMed Web of Science ®Google Scholar
• Ninomiya T. Epidemiological evidence of the relationship between diabetes and dementia. Adv Exp Med Biol. 2019;1128:13–25.
   PubMed Web of Science ®Google Scholar
• Paul KC, Jerrett M, Ritz B. Type 2 diabetes mellitus and Alzheimer’s disease: overlapping biologic mechanisms and environmental risk factors. Curr Environ Health Rep. 2018;5(1):44–58. doi:10.1007/s40572-018-0176-1
   PubMedGoogle Scholar
• Perumpail BJ, Khan MA, Yoo ER, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23(47):8263–8276. doi:10.3748/wjg.v23.i47.8263
   PubMed Web of Science ®Google Scholar
• Schwartz SS, Grant SFA, Herman ME. Intersections and clinical translations of diabetes mellitus with cancer promotion, progression and prognosis. Postgrad Med. 2019;131(8):597–606. doi:10.1080/00325481.2019.1657358
   PubMed Web of Science ®Google Scholar
• Strain WD, Paldánius PM. Diabetes, cardiovascular disease and the microcirculation. Cardiovasc Diabetol. 2018;17(1):57. doi:10.1186/s12933-018-0703-2
   PubMed Web of Science ®Google Scholar
• Wojciechowska J, Krajewski W, Bolanowski M, et al. Diabetes and cancer: a review of current knowledge. Exp Clin Endocrinol Diabetes. 2016;124(5):263–275. doi:10.1055/s-0042-100910
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. doi:10.1016/j.jhep.2019.06.021
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. IDF Diabetes Atlas. 9th ed. Brussels, Belgium; 2019. Available from: https://www.diabetesatlas.org. Accessed March 10, 2021.
   Google Scholar
• Campbell JM, Stephenson MD, de Courten B, et al. Metformin use associated with reduced risk of dementia in patients with diabetes: systematic review and meta-analysis. J Alzheimers Dis. 2018;65(4):1225–1236. doi:10.3233/JAD-180263
   PubMed Web of Science ®Google Scholar
• Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol. 2018;14(10):591–604. doi:10.1038/s41574-018-0048-7
   PubMed Web of Science ®Google Scholar
• Nguyen TT, Ta QTH, Nguyen TKO, et al. Type 3 diabetes and its role implications in Alzheimer’s disease. Int J Mol Sci. 2020;21(9):E3165. doi:10.3390/ijms21093165
   PubMed Web of Science ®Google Scholar
• Blázquez E, Velázquez E, Hurtado-Carneiro V, et al. Insulin in the brain: its pathophysiological implications for States related with central IR, type 2 diabetes and Alzheimer’s disease. Front Endocrinol (Lausanne). 2014;9(5):161.
   Google Scholar
• National Psoriasis Foundation. Statistics; 2019. Available from: https://www.psoriasis.org/content/statistics. Accessed September 21, 2020.
   Google Scholar
• Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–390. doi:10.1016/j.jaad.2016.07.064
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(1):84–91. doi:10.1001/2013.jamadermatol.406
   PubMed Web of Science ®Google Scholar
• Wan MT, Shin DB, Hubbard RA, et al. Psoriasis and the risk of diabetes: a prospective population-based cohort study. J Am Acad Dermatol. 2018;78(2):315–322.e1. doi:10.1016/j.jaad.2017.10.050
   PubMed Web of Science ®Google Scholar
• Flora GD, Nayak MK, Brief A. Review of cardiovascular diseases, associated risk factors and current treatment regimes. Curr Pharm Des. 2019;25(38):4063–4084.
   PubMed Web of Science ®Google Scholar
• Bertot LC, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 2016;17(5):E774. doi:10.3390/ijms17050774
   PubMed Web of Science ®Google Scholar
• Manne V, Handa P, Kowdley KV. Pathophysiology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Clin Liver Dis. 2018;22(1):23–37. doi:10.1016/j.cld.2017.08.007
   PubMed Web of Science ®Google Scholar
• Häring HU. Novel phenotypes of prediabetes? Diabetologia. 2016;59(9):1806–1818. doi:10.1007/s00125-016-4015-3
   PubMed Web of Science ®Google Scholar
• Goyal D, Limesand SW, Goyal R. Epigenetic responses and the developmental origins of health and disease. J Endocrinol. 2019;242(1):T105–T119. doi:10.1530/JOE-19-0009
   PubMed Web of Science ®Google Scholar
• Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. JAMA. 2017;318(19):1925–1926. doi:10.1001/jama.2017.17219
   PubMed Web of Science ®Google Scholar
• Hemani G, Zheng J, Elsworth B, et al. The MR-base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408. doi:10.7554/eLife.34408
   PubMed Web of Science ®Google Scholar
• Juvinao-Quintero DL, Hivert MF, Sharp GC, et al. DNA methylation and type 2 diabetes: the use of mendelian randomization to assess causality. Curr Genet Med Rep. 2019;7(4):191–207. doi:10.1007/s40142-019-00176-5
   PubMedGoogle Scholar
• Swerdlow DI. Mendelian randomization and type 2 diabetes. Cardiovasc Drugs Ther. 2016;30(1):51–57. doi:10.1007/s10557-016-6638-5
   PubMed Web of Science ®Google Scholar
• Yuan S, Kar S, Carter P, et al. Is type 2 diabetes causally associated with cancer risk? evidence from a two-sample mendelian randomization study. Diabetes. 2020;69(7):1588–1596. doi:10.2337/db20-0084
   PubMed Web of Science ®Google Scholar
• Carreras-Torres R, Johansson M, Gaborieau V, et al. The role of obesity, type 2 diabetes, and metabolic factors in pancreatic cancer: a mendelian randomization study. J Natl Cancer Inst. 2017;109(9):djx012. doi:10.1093/jnci/djx012
   PubMedGoogle Scholar
• Piñero J, Ramírez-Anguita JM, Saüch-Pitarch J, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 2020;48(D1):D845–D855. doi:10.1093/nar/gkz1021
   PubMed Web of Science ®Google Scholar
• Chen B, Li J, Chi D, et al. Non-coding RNAs in IGF-1R signaling regulation: the underlying pathophysiological link between diabetes and cancer. Cells. 2019;8(12):E1638. doi:10.3390/cells8121638
   PubMed Web of Science ®Google Scholar
• Thomassen JQ, Tolstrup JS, Benn M, et al. Type-2 diabetes and risk of dementia: observational and Mendelian randomisation studies in 1 million individuals. Epidemiol Psychiatr Sci. 2020;29:e118. doi:10.1017/S2045796020000347
   PubMed Web of Science ®Google Scholar
• Zhang W, Xin L, Lu Y. Integrative analysis to identify common genetic markers of metabolic syndrome, dementia, and diabetes. Med Sci Monit. 2017;23:5885–5891. doi:10.12659/MSM.905521
   PubMed Web of Science ®Google Scholar
• Wang J, Gong B, Zhao W, et al. Epigenetic mechanisms linking diabetes and synaptic impairments. Diabetes. 2014;63(2):645–654. doi:10.2337/db13-1063
   PubMed Web of Science ®Google Scholar
• David T, Ling SF, Barton A. Genetics of immune-mediated inflammatory diseases. Clin Exp Immunol. 2018;193(1):3–12. doi:10.1111/cei.13101
   PubMed Web of Science ®Google Scholar
• Wang H, Wang Z, Rani PL, et al. Identification of PTPN22, ST6GAL1 and JAZF1 as psoriasis risk genes demonstrates shared pathogenesis between psoriasis and diabetes. Exp Dermatol. 2017;26(11):1112–1117. doi:10.1111/exd.13393
   PubMed Web of Science ®Google Scholar
• Granata M, Skarmoutsou E, Trovato C, et al. Obesity, type 1 diabetes, and psoriasis: an autoimmune triple flip. Pathobiology. 2017;84(2):71–79. doi:10.1159/000447777
   PubMed Web of Science ®Google Scholar
• Ahmad OS, Morris JA, Mujammami M, et al. A Mendelian randomization study of the effect of type-2 diabetes on coronary heart disease. Nat Commun. 2015;6(1):7060. doi:10.1038/ncomms8060
   PubMed Web of Science ®Google Scholar
• Murea M, Ma L, Freedman BI. Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications. Rev Diabet Stud. 2012;9(1):6–22. doi:10.1900/RDS.2012.9.6
   PubMedGoogle Scholar
• Costantino S, Mohammed SA, Ambrosini S, et al. Epigenetic processing in cardiometabolic disease. Atherosclerosis. 2019;281:150–158. doi:10.1016/j.atherosclerosis.2018.09.029
   PubMed Web of Science ®Google Scholar
• Paneni F, Costantino S, Battista R, et al. Adverse epigenetic signatures by histone methyltransferase Set7 contribute to vascular dysfunction in patients with type 2 diabetes mellitus. Circ Cardiovasc Genet. 2015;8(1):150–158. doi:10.1161/CIRCGENETICS.114.000671
   PubMedGoogle Scholar
• Ferrannini G, Manca ML, Magnoni M, et al. Coronary artery disease and type 2 diabetes: a Proteomic Study. Diabetes Care. 2020;43(4):843–851. doi:10.2337/dc19-1902
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang Y, Graham S, et al. Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. J Hepatol. 2020;73(2):263–276. doi:10.1016/j.jhep.2020.03.006
   PubMed Web of Science ®Google Scholar
• Sookoian S, Pirola CJ. Genetics of nonalcoholic fatty liver disease: from pathogenesis to therapeutics. Semin Liver Dis. 2019;39(2):124–140. doi:10.1055/s-0039-1679920
   PubMed Web of Science ®Google Scholar
• de Mello VD, Matte A, Perfilyev A, et al. Human liver epigenetic alterations in non-alcoholic steatohepatitis are related to insulin action. Epigenetics. 2017;12(4):287–295. doi:10.1080/15592294.2017.1294305
   PubMed Web of Science ®Google Scholar
• Yuan S, Larsson SC. An atlas on risk factors for type 2 diabetes: a wide-angled Mendelian randomisation study [published online ahead of print, 2020 Sep 8]. Diabetologia. 2020;10.1007/s00125-020-05253-x.
   Web of Science ®Google Scholar
• Censin JC, Nowak C, Cooper N, et al. Childhood adiposity and risk of type 1 diabetes: a Mendelian randomization study. PLoS Med. 2017;14(8):e1002362. doi:10.1371/journal.pmed.1002362
   PubMed Web of Science ®Google Scholar
• Shu X, Wu L, Khankari NK, et al. Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. Int J Epidemiol. 2019;48(3):795–806. doi:10.1093/ije/dyy201
   PubMed Web of Science ®Google Scholar
• Ravichandran G, Lakshmanan DK, Raju K, et al. Food advanced glycation end products as potential endocrine disruptors: an emerging threat to contemporary and future generation. Environ Int. 2019;123:486–500. doi:10.1016/j.envint.2018.12.032
   PubMed Web of Science ®Google Scholar
• Benn M, Nordestgaard BG, Tybjærg-Hansen A, et al. Impact of glucose on risk of dementia: Mendelian randomisation studies in 115,875 individuals. Diabetologia. 2020;63(6):1151–1161. doi:10.1007/s00125-020-05124-5
   PubMed Web of Science ®Google Scholar
• Zeng J, Luo S, Huang Y, et al. Critical role of environmental factors in the pathogenesis of psoriasis. J Dermatol. 2017;44(8):863–872. doi:10.1111/1346-8138.13806
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5–21. doi:10.1111/dom.13129
   PubMed Web of Science ®Google Scholar
• Gyldenløve M, Vilsbøll T, Zachariae C, et al. Impaired incretin effect is an early sign of glucose dysmetabolism in nondiabetic patients with psoriasis. J Int Med. 2015;278(6):660–670. doi:10.1111/joim.12388
   PubMed Web of Science ®Google Scholar
• Budu-Aggrey A, Brumpton B, Tyrrell J, et al. Evidence of a causal relationship between body mass index and psoriasis: a mendelian randomization study. PLoS Med. 2019;16(1):e1002739. doi:10.1371/journal.pmed.1002739
   PubMed Web of Science ®Google Scholar
• Ogawa K, Stuart PE, Tsoi LC, et al. A transethnic mendelian randomization study identifies causality of obesity on risk of psoriasis. J Invest Dermatol. 2019;139(6):1397–1400. doi:10.1016/j.jid.2018.11.023
   PubMed Web of Science ®Google Scholar
• Fang X, Zuo J, Zhou J, et al. Childhood obesity leads to adult type 2 diabetes and coronary artery diseases: a 2-sample mendelian randomization study. Medicine (Baltimore). 2019;98(32):e16825. doi:10.1097/MD.0000000000016825
   PubMed Web of Science ®Google Scholar
• Yang Q, Lin SL, Kwok MK, et al. The roles of 27 genera of human gut microbiota in ischemic heart disease, type 2 diabetes mellitus, and their risk factors: a mendelian randomization study. Am J Epidemiol. 2018;187(9):1916–1922. doi:10.1093/aje/kwy096
   PubMed Web of Science ®Google Scholar
• Sircana A, Framarin L, Leone N, et al. Altered gut microbiota in type 2 diabetes: just a coincidence? Curr Diab Rep. 2018;18(10):98. doi:10.1007/s11892-018-1057-6
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Kountouras J, Deretzi G, et al. The emerging role of endocrine disruptors in pathogenesis of insulin resistance: a concept implicating nonalcoholic fatty liver disease. Curr Mol Med. 2012;12(1):68–82. doi:10.2174/156652412798376161
   PubMed Web of Science ®Google Scholar
• de la Monte SM. Insulin resistance and neurodegeneration: progress towards the development of new therapeutics for Alzheimer’s disease. Drugs. 2017;77(1):47–65.
   PubMed Web of Science ®Google Scholar
• Newcombe EA, Camats-Perna J, Silva ML, Valmas N, Huat TJ, Medeiros R. Inflammation: the link between comorbidities, genetics, and Alzheimer’s disease. J Neuroinflammation. 2018;15(1):276.
   PubMed Web of Science ®Google Scholar
• Chiu HY, Hung CJ, Muo CH, et al. The bidirectional association between type 2 diabetes and psoriasis: two retrospective cohort studies. Indian J Dermatol Venereol Leprol. 2020;86(4):366–374. doi:10.4103/ijdvl.IJDVL_428_18
   PubMed Web of Science ®Google Scholar
• Polic MV, Miskulin M, Smolic M, et al. Psoriasis severity-a risk factor of insulin resistance independent of metabolic syndrome. Int J Environ Res Public Health. 2018;15(7):1486. doi:10.3390/ijerph15071486
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhu Y, Lian N, et al. Metabolic syndrome and skin diseases. Front Endocrinol. 2019;10.
   PubMedGoogle Scholar
• Di Pino A, DeFronzo RA. Insulin resistance and atherosclerosis: implications for insulin-sensitizing agents. Endocr Rev. 2019;40(6):1447–1467.
   PubMed Web of Science ®Google Scholar
• Katakami N. Mechanism of development of atherosclerosis and cardiovascular disease in diabetes mellitus. J Atheroscler Thromb. 2018;25(1):27–39. doi:10.5551/jat.RV17014
   PubMed Web of Science ®Google Scholar
• Roizen JD, Bradfield JP, Hakonarson H. Progress in understanding type 1 diabetes through its genetic overlap with other autoimmune diseases. Curr Diab Rep. 2015;15(11):102. doi:10.1007/s11892-015-0668-4
   PubMed Web of Science ®Google Scholar
• Bost F, Rena G, Viollet B. Editorial: metformin: beyond diabetes. Front Endocrinol (Lausanne). 2019;10(10):851. doi:10.3389/fendo.2019.00851
   PubMed Web of Science ®Google Scholar
• Wilkin TJ. The accelerator hypothesis: a review of the evidence for insulin resistance as the basis for type I as well as type II diabetes. Int J Obes (Lond). 2009;33(7):716–726. doi:10.1038/ijo.2009.97
   PubMed Web of Science ®Google Scholar
• Martin SD, McGee SL. Metabolic reprogramming in type 2 diabetes and the development of breast cancer. J Endocrinol. 2018;237(2):R35–R46. doi:10.1530/JOE-18-0037
   PubMed Web of Science ®Google Scholar
• Walter S, Marden JR, Kubzansky LD, et al. Diabetic phenotypes and late-life dementia risk: a Mechanism-Specific Mendelian Randomization Study. Alzheimer Dis Assoc Disord. 2016;30(1):15–20. doi:10.1097/WAD.0000000000000128
   PubMed Web of Science ®Google Scholar
• Gyldenløve M, Storgaard H, Holst JJ, et al. Patients with psoriasis are insulin resistant. J Am Acad Dermatol. 2015;72(4):599–605. doi:10.1016/j.jaad.2015.01.004
   PubMed Web of Science ®Google Scholar
• Zaharia OP, Strassburger K, Strom A, et al.; German Diabetes Study Group. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol. 2019;7(9):684–694. doi:10.1016/S2213-8587(19)30187-1.
   PubMed Web of Science ®Google Scholar
• De silva NMG, Borges MC, Hingorani AD, et al. Liver function and risk of type 2 diabetes: bidirectional Mendelian randomization study. Diabetes. 2019;68(8):1681–1691. doi:10.2337/db18-1048
   PubMed Web of Science ®Google Scholar
• Scheiner G, Schwarz SS, Herman ME. Managing diabetes by maintaining healthier beta cells: a fresh perspective for diabetes educators. AADE Pract. 2018;6(4):12–18. doi:10.1177/2325160318781529
   Google Scholar
• Pareek KK, Mathur G, Ramchandani GD. Anti-diabetic agent and cancer. J Assoc Physicians India. 2019;67(10):66–69.
   PubMedGoogle Scholar
• Bendlin BB. Antidiabetic therapies and Alzheimer disease. Dialogues Clin Neurosci. 2019;21(1):83–91.
   PubMed Web of Science ®Google Scholar
• Chou PS, Ho BL, Yang YH. Effects of pioglitazone on the incidence of dementia in patients with diabetes. J Diabetes Complications. 2017;31(6):1053–1057. doi:10.1016/j.jdiacomp.2017.01.006
   PubMed Web of Science ®Google Scholar
• Lu CH, Yang CY, Li CY, et al. Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study. Diabetologia. 2018;61(3):562–573. doi:10.1007/s00125-017-4499-5
   PubMed Web of Science ®Google Scholar
• Tseng CH. Pioglitazone reduces dementia risk in patients with type 2 diabetes mellitus: a retrospective cohort analysis. J Clin Med. 2018;7(10):E306. doi:10.3390/jcm7100306
   PubMed Web of Science ®Google Scholar
• Chang G, Wang J, Song J, et al. Efficacy and safety of pioglitazone for treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. J Dermatolog Treat. 2019;1–7.
   Google Scholar
• Oseini AM, Sanyal AJ. Therapies in non-alcoholic steatohepatitis (NASH). Liver Int. 2017;37(Suppl 1):97–103. doi:10.1111/liv.13302
   PubMed Web of Science ®Google Scholar
• Jenkins AJ, Welsh P, Petrie JR. Metformin, lipids and atherosclerosis prevention. Curr Opin Lipidol. 2018;29(4):346–353. doi:10.1097/MOL.0000000000000532
   PubMed Web of Science ®Google Scholar
• Iogna Prat L, Tsochatzis EA. The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). Hormones (Athens). 2018;17(2):219–229. doi:10.1007/s42000-018-0021-9
   PubMedGoogle Scholar
• Smith BK, Marcinko K, Desjardins EM, et al. Treatment of nonalcoholic fatty liver disease: role of AMPK. Am J Physiol Endocrinol Metab. 2016;311(4):E730–E740. doi:10.1152/ajpendo.00225.2016
   PubMed Web of Science ®Google Scholar
• Aroda VR. A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials. Diabetes Obes Metab. 2018;20(Suppl 1):22–33. doi:10.1111/dom.13162
   PubMed Web of Science ®Google Scholar
• Cao C, Yang S, Zhou Z. GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials. Endocrine. 2019;66(2):157–165. doi:10.1007/s12020-019-02055-z
   PubMed Web of Science ®Google Scholar
• Grieco M, Giorgi A, Gentile MC, et al. Glucagon-like peptide-1: a focus on neurodegenerative diseases. Front Neurosci. 2019;18(13):1112. doi:10.3389/fnins.2019.01112
   Web of Science ®Google Scholar
• Petit JM, Vergès B. GLP-1 receptor agonists in NAFLD. Diabetes Metab. 2017;43(Suppl 1):2S28–2S33. doi:10.1016/S1262-3636(17)30070-8
   PubMed Web of Science ®Google Scholar
• Seghieri M, Christensen AS, Andersen A, et al. Future perspectives on GLP-1 receptor agonists and GLP-1/glucagon receptor co-agonists in the treatment of NAFLD. Front Endocrinol (Lausanne). 2018;9:649. doi:10.3389/fendo.2018.00649
   PubMed Web of Science ®Google Scholar
• Isik AT, Soysal P, Yay A, et al. The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer’s disease. Diabetes Res Clin Pract. 2017;123:192–198. doi:10.1016/j.diabres.2016.12.010
   PubMed Web of Science ®Google Scholar
• Prattichizzo F, De Nigris V, Micheloni S, et al. Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: is low-grade inflammation the neglected component? Diabetes Obes Metab. 2018;20(11):2515–2522. doi:10.1111/dom.13488
   PubMed Web of Science ®Google Scholar
• Raj H, Durgia H, Palui R, et al. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: a systematic review. World J Diabetes. 2019;10(2):114–132. doi:10.4239/wjd.v10.i2.114
   PubMed Web of Science ®Google Scholar
• Chamarthi B, Gaziano JM, Blonde L, et al. Timed bromocriptine-QR therapy reduces progression of cardiovascular disease and dysglycemia in subjects with well-controlled type 2 diabetes mellitus. J Diabetes Res. 2015;2015:157698. doi:10.1155/2015/157698
   PubMed Web of Science ®Google Scholar
• Gaziano JM, Cincotta AH, Vinik A, et al. Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. J Am Heart Assoc. 2012;1(5):e002279. Erratum in: J Am Heart Assoc. 2015; 4(10). doi:10.1161/JAHA.112.002279
   PubMed Web of Science ®Google Scholar
• Ursini F, Russo E, De Giorgio R, et al. Current treatment options for psoriatic arthritis: spotlight on abatacept. Ther Clin Risk Manag. 2018;14:1053–1059. doi:10.2147/TCRM.S148586
   PubMed Web of Science ®Google Scholar
• Ursini F, Russo E, Letizia Hribal M, et al. Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study. Medicine (Baltimore). 2015;94(21):e888. doi:10.1097/MD.0000000000000888
   PubMed Web of Science ®Google Scholar
• Rachid O, Osman A, Abdi R, et al. CTLA4-Ig (abatacept): a promising investigational drug for use in type 1 diabetes. Expert Opin Investig Drugs. 2020;29(3):221–236. doi:10.1080/13543784.2020.1727885
   PubMed Web of Science ®Google Scholar
• Simmons K, Michels AW. Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease. Rheum Dis Clin North Am. 2014;40(4):797–811. doi:10.1016/j.rdc.2014.07.008
   PubMed Web of Science ®Google Scholar